DUBLIN – Galapagos NV piled on the good news for investors Tuesday, unveiling 12-week phase IIb rheumatoid arthritis (RA) data for its selective Janus kinase 1 (JAK1) inhibitor filgotinib as a monotherapy, which could eventually help to line it up as a potential contender in first-line therapy but in the short term confirms the strong efficacy signal it recently reported from a phase IIb trial of the drug administered in combination with methotrexate.